AngioSoma Inc
GlobeStar Therapeutics Corporation, a clinical stage pharmaceutical company, engages in the provision of patented formulation of drugs for the treatment of multiple sclerosis and other neurodegenerative diseases in the United States. The company was formerly known as AngioSoma, Inc. and changed its name to GlobeStar Therapeutics Corporation in July 2021. GlobeStar Therapeutics Corporation is base… Read more
AngioSoma Inc (GSTC) - Net Assets
Latest net assets as of September 2024: $-1.62 Million USD
Based on the latest financial reports, AngioSoma Inc (GSTC) has net assets worth $-1.62 Million USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($83.87K) and total liabilities ($1.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.62 Million |
| % of Total Assets | -1937.35% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3101.27 |
AngioSoma Inc - Net Assets Trend (2010–2023)
This chart illustrates how AngioSoma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for AngioSoma Inc (2010–2023)
The table below shows the annual net assets of AngioSoma Inc from 2010 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-09-30 | $-1.43 Million | -20.03% |
| 2022-12-31 | $-1.19 Million | 0.00% |
| 2022-09-30 | $-1.19 Million | -64.58% |
| 2021-12-31 | $-725.82K | 0.00% |
| 2021-09-30 | $-725.82K | -10.10% |
| 2020-12-31 | $-659.22K | 0.00% |
| 2020-09-30 | $-659.22K | +3.82% |
| 2019-09-30 | $-685.43K | +21.28% |
| 2018-09-30 | $-870.73K | -39.55% |
| 2017-09-30 | $-623.98K | +25.99% |
| 2016-09-30 | $-843.09K | -6769.47% |
| 2015-09-30 | $12.64K | +112.10% |
| 2014-09-30 | $-104.44K | -142.58% |
| 2013-09-30 | $245.28K | +331.11% |
| 2012-09-30 | $-106.13K | -996.09% |
| 2011-09-30 | $-9.68K | -239.89% |
| 2010-09-30 | $6.92K | -- |
Equity Component Analysis
This analysis shows how different components contribute to AngioSoma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2045194700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $996.12K | % |
| Other Comprehensive Income | $-1.43 Million | % |
| Other Components | $19.46 Million | % |
| Total Equity | $-1.43 Million | 100.00% |
AngioSoma Inc Competitors by Market Cap
The table below lists competitors of AngioSoma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BKXI39
SA:BKXI39
|
$124.13K |
|
Terra Property Trust, Inc. 6.00%
NYSE:TPTA
|
$124.20K |
|
Nuveen Churchill Direct Lending Corp.
NYSE:NCDL
|
$124.22K |
|
Neuberger Berman Next Generation Connectivity Fund Inc
NYSE:NBXG
|
$124.32K |
|
Cbd Life Sciences Inc
PINK:CBDL
|
$124.07K |
|
Golub Capital BDC Inc
NASDAQ:GBDC
|
$123.99K |
|
ATLANTA ELECTRICALS LTD
NSE:ATLANTAELE
|
$123.95K |
|
Global Hemp Group Inc
PINK:GBHPF
|
$123.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in AngioSoma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2023, total equity changed from -1,433,861 to -1,433,861, a change of 0.
- Net loss of 1,487,810 reduced equity.
- Other comprehensive income decreased equity by 1,433,990.
- Other factors increased equity by 2,921,800.
Equity Change Factors (2023 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.49 Million | -103.76% |
| Other Comprehensive Income | $-1.43 Million | -100.01% |
| Other Changes | $2.92 Million | +203.77% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares AngioSoma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-09-30 | $1.54 | $0.00 | x |
| 2011-09-30 | $-1.87 | $0.00 | x |
| 2012-09-30 | $-11.34 | $0.00 | x |
| 2013-09-30 | $31.08 | $0.00 | x |
| 2014-09-30 | $-0.63 | $0.00 | x |
| 2015-09-30 | $0.01 | $0.00 | x |
| 2016-09-30 | $-0.03 | $0.00 | x |
| 2017-09-30 | $-0.02 | $0.00 | x |
| 2018-09-30 | $-0.02 | $0.00 | x |
| 2019-09-30 | $-0.01 | $0.00 | x |
| 2020-09-30 | $0.00 | $0.00 | x |
| 2020-12-31 | $0.00 | $0.00 | x |
| 2021-09-30 | $0.00 | $0.00 | x |
| 2021-12-31 | $0.00 | $0.00 | x |
| 2022-09-30 | $0.00 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-09-30 | $0.00 | $0.00 | x |
| 2023-12-31 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently AngioSoma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-500.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | -30.02% | 0.00% | 0.00x | 1.29x | $-2.77K |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-53.14K |
| 2012 | 0.00% | 0.00% | -1.00x | 0.00x | $-1.08 Million |
| 2013 | -385.72% | -1649.40% | 0.12x | 1.89x | $-970.64K |
| 2014 | 0.00% | -1280.18% | 0.20x | 0.00x | $-1.23 Million |
| 2015 | -8591.09% | -2576.33% | 0.13x | 25.50x | $-1.09 Million |
| 2016 | 0.00% | -5.56% | 3428.63x | 0.00x | $-3.21 Million |
| 2017 | 0.00% | -2.28% | 3003.99x | 0.00x | $-1.62 Million |
| 2018 | 0.00% | -91797.75% | 0.01x | 0.00x | $-729.93K |
| 2019 | 0.00% | -158823.53% | 0.00x | 0.00x | $-606.46K |
| 2020 | 0.00% | -703896.10% | 0.00x | 0.00x | $-476.08K |
| 2020 | 0.00% | -1012715.58% | 0.00x | 0.00x | $-713.87K |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.73 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.60 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.37 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.52 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.34 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.34 Million |
Industry Comparison
This section compares AngioSoma Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| AngioSoma Inc (GSTC) | $-1.62 Million | -30.02% | N/A | $124.11K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |